Search details
1.
DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo.
Small
; 18(26): e2108063, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35633287
2.
Simulated confluence on micropatterned substrates correlates responses regulating cellular differentiation.
Biotechnol Bioeng
; 119(6): 1641-1659, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35192191
3.
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
Blood
; 132(10): 1039-1049, 2018 09 06.
Article
in English
| MEDLINE | ID: mdl-30018078
4.
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
Blood
; 131(17): 1910-1919, 2018 04 26.
Article
in English
| MEDLINE | ID: mdl-29437592
5.
Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease.
Am J Transplant
; 19(6): 1820-1830, 2019 06.
Article
in English
| MEDLINE | ID: mdl-30748099
6.
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
N Engl J Med
; 374(4): 323-32, 2016 Jan 28.
Article
in English
| MEDLINE | ID: mdl-26641137
7.
Illness Perceptions in Chronic Lymphocytic Leukemia: Testing Leventhal's Self-regulatory Model.
Ann Behav Med
; 53(9): 839-848, 2019 08 16.
Article
in English
| MEDLINE | ID: mdl-30590383
8.
The Significance of Left Axis Deviation in the Pediatric Population: A Meta-Analysis.
Pediatr Cardiol
; 40(4): 677-684, 2019 Apr.
Article
in English
| MEDLINE | ID: mdl-30879085
9.
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
Biochemistry
; 57(26): 3564-3575, 2018 07 03.
Article
in English
| MEDLINE | ID: mdl-29851337
10.
Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia.
Cancer
; 124(15): 3240-3248, 2018 08 01.
Article
in English
| MEDLINE | ID: mdl-29757455
11.
Targeting BTK through microRNA in chronic lymphocytic leukemia.
Blood
; 128(26): 3101-3112, 2016 12 29.
Article
in English
| MEDLINE | ID: mdl-27756747
12.
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Blood
; 127(9): 1117-27, 2016 Mar 03.
Article
in English
| MEDLINE | ID: mdl-26813675
13.
Cancer-Specific Stress and Trajectories of Psychological and Physical Functioning in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia.
Ann Behav Med
; 52(4): 287-298, 2018 03 15.
Article
in English
| MEDLINE | ID: mdl-30084895
14.
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
N Engl J Med
; 370(24): 2286-94, 2014 Jun 12.
Article
in English
| MEDLINE | ID: mdl-24869598
15.
Targeted therapies in CLL: mechanisms of resistance and strategies for management.
Blood
; 126(4): 471-7, 2015 Jul 23.
Article
in English
| MEDLINE | ID: mdl-26065659
16.
Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling.
Blood
; 125(21): 3297-305, 2015 May 21.
Article
in English
| MEDLINE | ID: mdl-25833959
17.
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.
Blood
; 125(20): 3128-32, 2015 May 14.
Article
in English
| MEDLINE | ID: mdl-25838351
18.
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
Blood
; 125(16): 2497-506, 2015 Apr 16.
Article
in English
| MEDLINE | ID: mdl-25700432
19.
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
Blood
; 126(7): 842-50, 2015 Aug 13.
Article
in English
| MEDLINE | ID: mdl-26116658
20.
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
Blood
; 126(1): 61-8, 2015 Jul 02.
Article
in English
| MEDLINE | ID: mdl-25972157